连续性肾脏替代治疗联合血液灌流治疗脓毒症的临床效果<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2026.09.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1125 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the clinical efficacy of continuous renal replacement therapy (CRRT) combined with hemoperfusion in patients with sepsis. 【Methods】A total of 80 patients with sepsis admitted to Binzhou People's Hospital from May 2023 to August 2025 were randomly assigned to the control group (treated with CRRT alone) and the observation group (treated with CRRT combined with hemoperfusion), with 40 patients in each group. The recovery time, tissue perfusion indicators, inflammatory factors, T lymphocyte subsets, health status, and mortality rate were compared between the two groups. 【Results】 Compared with the control group, the duration of mechanical ventilation and length of ICU stay were shorter in the observation group (all P<0.05). After treatment, the mean arterial pressure (MAP) was higher, and lactate level was lower in the observation group than those in the control group (all P<0.05). The levels of inflammatory factors in the observation group were lower than those in the control group (all P<0.05). The observation group exhibited higher total lymphocyte count (LYM), Th cells, and CD4⁺/CD8⁺ ratios compared to the control group (all P<0.05). The acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score in the observation group was lower than that in the control group (P<0.05). There was no statistically significant difference in 28-day mortality between the two groups (P>0.05). 【Conclusion】 CRRT combined with hemoperfusion can effectively shorten recovery time, improve immune function, inflammatory factor levels, and health status in patients with sepsis, providing an effective therapeutic strategy for sepsis management.

Key words： Sepsis Continuous Renal Replacement Therapy Hemoperfusion

Received: 11 February 2026

PACS:

R631

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIN Shuzhen
	HU Xiaohuaa
	LIU Xiaoying
	DING Chaob

Cite this article:

XIN Shuzhen,HU Xiaohuaa,LIU Xiaoying, et al. Clinical Efficacy of Continuous Renal Replacement Therapy Combined with Hemoperfusion in the Treatment of Sepsis[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(9): 1412-1415.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.09.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I9/1412

[1] 徐文静,张万乾,张建平,等. 脓毒症患者血浆维生素B₁缺乏与乳酸酸中毒的关系[J]. 中华医院感染学杂志,2025,35(12):1798-1802.
[2] 江仁,欧阳招兰,易思奇. 脓毒症血清降钙素原清除与28 d院内死亡风险的相关性[J]. 中华医院感染学杂志,2025,35(21):3254-3259.
[3] 秦锋周,陈天晓,余虹,等. 基于热毒理论探讨清瘟败毒饮联合血净对脓毒症巨噬细胞极化的影响[J]. 中华医院感染学杂志,2025,35(23):3549-3553.
[4] 许晓函,胡威龙,王润珠,等. 西维来司他钠治疗时机对脓毒症急性呼吸窘迫综合征患者的影响[J]. 实用心脑肺血管病杂志,2025,33(1):94-97.
[5] 陈阳琴,齐文杰. 米卡芬净联合连续性肾脏替代治疗脓毒症伴真菌感染患者的临床结局探究[J]. 川北医学院学报,2024,39(9):1187-1190.
[6] 曹钰,柴艳芬,邓颖,等.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 临床急诊杂志,2018,19(9) : 567-588.
[7] Evansl L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of Sepsis and Septic Shock 2021[J]. Crit Care Med, 2021, 49(11):1063-1143.
[8] 梁子宏,陈奕睿,陈铭君,等. 血小板、血乳酸联合APACHE Ⅱ评分预测脓毒症患者院内死亡[J]. 岭南急诊医学杂志,2025,30(6):629-632.
[9] 周紫毅,鄢雨菲,杨美霞,等. 可溶性白细胞分化抗原14亚型在脓毒症中的研究进展[J]. 西部医学,2026,38(1):142-145.
[10] 雷斯媛,冯贞贞,春柳,等. 基于横断面调查的脓毒症中医证候分布相关因素分析[J]. 世界科学技术-中医药现代化,2025,27(11):3316-3327.
[11] 冯贵玉,李华,李博冉,等. NETosis在脓毒症中作用机制及治疗方案的研究进展[J]. 中国医学前沿杂志(电子版),2025,17(4):117-122.
[12] 肖惠,黎上琳,冯新程,等. 不同CRRT治疗剂量对严重脓毒症患者血清PGE2和I-FABP水平及预后的影响[J]. 中国临床研究,2025,38(11):1675-1678.
[13] 缪锦松,黎代强,陈琳. 血必净注射液联合HA330血液灌流对急性脓毒症合并AKI患者的疗效分析[J]. 中国医学创新,2025,22(12):33-37.
[14] 李丽丽,吴晨晨,闫艳玲. 连续性肾脏替代治疗联合血液灌流对脓毒症患者临床疗效的影响[J]. 中国中西医结合急救杂志,2023,30(3):304-307.